lowltn14
Iron
- Joined
- Dec 13, 2025
- Posts
- 11
- Reputation
- 5
Using Steroids With Almost Zero Sides
Use of anabolic-androgenic steroids (AAS) at supraphysiological doses can cause a cascade of systemic stress that far exceeds the intended muscle-building and performance-enhancing effects. These compounds, especially the 17α-alkylated oral agents and non-aromatizable DHT derivatives, disturb normal homeostasis in multiple organ systems. The side effects of AAS can be divided into four major categories. They are cardiovascular stress due to hypertension and water retention, unfavorable changes in blood lipids, induction of insulin resistance, and severe skin disorders such as cystic acne. Each ancillary medication is selected to address one of these issues, offering a harm-reduction approach which can almost completely eliminate the associated risks.
1. Blood Pressure and Heart Strain: The RAAS and Sympathetic Nervous System
Aromatizable androgens like testosterone stimulate the renin-angiotensin-aldosterone system (RAAS) that leads to sodium and water retention. This leads to an increased blood volume and places more strain on the heart. Androgens also stimulate the sympathetic nervous system, increasing resting heart rate and cardiac output. These effects are compounded when users stack steroids with stimulants such as Clenbuterol. This combination of high blood pressure and increased heart rate can lead to left ventricular hypertrophy and other forms of cardiac damage over time.- Telmisartan (ARB): This drug blocks the angiotensin II type 1 receptor, directly reducing vasoconstriction and fluid retention caused by RAAS activation. At its normal dose of 40 to 80 milligrams its main benefit is control of blood pressure but it also causes mild insulin-sensitizing effects via PPARγ agonism.
- Nebivolol (β1-Blocker): Unlike the older beta blockers, this has a unique vasodilating effect via the release of nitric oxide. This makes it more suitable for athletes, as it does not limit exercise capacity as much. This can be especially useful if you have a high resting heart rate from stimulants.
- Eplerenone (MRA): This medication directly antagonizes the action of aldosterone at the mineralocorticoid receptor without allowing sodium retention and potassium excretion. Eplerenone is preferred to spironolactone since this medication has no impact on androgen receptors, which means that it will not influence the effectiveness of the steroid cycle. Moreover, besides the diuretic properties, eplerenone directly affects the fibrosis of the heart, which is needed to compensate for the cardiac remodeling provoked by the usage of AAS.
- HCTZ (Thiazide): The diuretic acts by suppressing sodium reabsorption from the kidney. However, there are a number of complications associated with the use of HCTZ such as hypokalemia and hyperglycemia. Thus, when using an AAS cycle, during which the aldosterone level becomes high, it is better to use eplerenone with HCTZ being used in case of persistent hypertension.
- Empagliflozin (SGLT2i): The drug was initially developed to treat diabetes and helps excrete sodium and glucose from the body. Empagliflozin reduces blood volume and, hence, the blood pressure. There is evidence of its cardiovascular protective effects obtained in clinical trials.
2. Lipid Disruption: The Problem of HDL and LDL Imbalance
Steroids affect the process of lipid metabolism by enhancing the function of hepatic lipase, an enzyme involved in the breakdown of high-density lipoprotein (HDL) cholesterol. Also, the steroids increase the level of low-density lipoprotein (LDL) cholesterol. It should be noted that oral steroids have more dangerous effects on the process of lipid metabolism because they pass through the liver before entering the bloodstream.- Ezetimibe (NPC1L1 inhibitor): The medicine reduces cholesterol intake from the gut, thereby reducing LDL levels. It is usually prescribed initially for AAS patients because it has no adverse effect on the liver. This characteristic is especially important for patients taking hepatotoxic oral steroids.
- Rosuvastatin (statin): This drug is prescribed to control LDL levels if it was not achieved using ezetimibe. This statin is preferable to atorvastatin because it interacts less with the liver enzymes, and there is a smaller risk of drug interaction. Even at the dose of 10 mg, the risk of muscle damage is minimal.
3. Insulin Resistance and Metabolic Disruption
Some anabolic steroids, particularly 19-nortestosterone derivatives like Trenbolone, interfere with the body's ability to process glucose. This leads to insulin resistance in the liver and muscles. The use of growth hormone compounds can worsen this effect by promoting glucose production and fat breakdown, increasing the risk of metabolic problems.- Empagliflozin (SGLT2i): In addition to its blood pressure benefits, this drug lowers blood sugar by causing the kidneys to excrete excess glucose. This reduces the burden on the liver and improves the body's sensitivity to insulin. It is arguably the most well-supported medication for counteracting the metabolic side effects of AAS.
4. Skin and Acne: The Androgenic Effect on Sebaceous Glands
DHT-derived steroids such as Masteron, Winstrol, and Proviron are powerful activators of androgen receptors in the skin. This stimulates the sebaceous glands to produce excess oil, leading to clogged pores and severe inflammatory acne. Standard topical treatments and antibiotics are generally ineffective against this type of androgenic acne.- Isotretinoin (Retinoid): This drug is known to address all four main contributors of acne development such as oil secretion, cell turnover, bacterial population, and inflammation. While the conventional dosage regimen calls for achieving the total cumulative dose of 120 to 150 mg per kg of body mass, most AAS users take 20-40 mg daily in order to alleviate the symptoms during their cycle. Nevertheless, isotretinoin increases the level of liver enzymes and lipids, hence the necessity of routine blood tests.
- 5. Lipid Profile Improvement and PPARδ Activation
- Cardarine (GW50156): This substance stimulates the activity of PPARδ, which is responsible for lipid metabolism. It improves the ratio of HDL to LDL and promotes fat loss. Despite development for this compound being stopped after cancer conerns during pharmaceutical phase trials, the actual methodology of the studies is incongruent to what would be expected in real-life dosing of cardarine.
Conclusion: A Comprehensive and Near Perfect Strategy
Managing the side effects of anabolic steroid use requires a detailed understanding of how these drugs interact with the body. For example, combining telmisartan and eplerenone requires careful monitoring of potassium levels, as both drugs can increase the risk of hyperkalemia. Similarly, the lipid-lowering effects of ezetimibe and cardarine must be weighed against the potential for isotretinoin to raise triglycerides and LDL. These new side effects from the ancilliaries however carry a fraction of the negative health outcomes comapred to steroid use without ancilliaries. This approach eliminiates the vast majority of risks associated with PED usage, and leads to a minimal to non-existant impact on lifespan and greater health outcomes.References
Baggish, A. L., Weiner, R. B., Kanayama, G., Hudson, J. I., Lu, M. T., Hoffmann, U., & Pope, H. G. (2017). Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation, 135(21), 1991-2002.Bhasin, S., Hatfield, D. L., Hoffman, J. R., Kraemer, W. J., Labotz, M., Phillips, S. M., & Ratamess, N. A. (2015). Anabolic-androgenic steroid use in sports, health, and society. Medicine and Science in Sports and Exercise, 47(8), 1723-1734.
Ferrario, C. M., & Strawn, W. B. (2006). Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. The American Journal of Cardiology, 98(1), 121-128.
Fitchev, P., Rademaker, A., & Crawford, S. E. (2016). Isotretinoin and the role of retinoids in acne management. Journal of the American Academy of Dermatology, 74(5), 945-953.
Meli, R., & Nuzzo, D. (2021). Anabolic-androgenic steroid use and its effects on lipid profile: A clinical review. Journal of Clinical Medicine, 10(4), 742.
Nelson, A. J., & Peterson, J. L. (2019). Role of SGLT2 inhibitors in cardiovascular risk reduction: Insights from clinical trials. Circulation Research, 124(9), 1322-1334.
Pope, H. G., Kanayama, G., & Hudson, J. I. (2020). Risk factors for anabolic-androgenic steroid use and adverse health outcomes. Current Opinion in Endocrinology, Diabetes and Obesity, 27(6), 362-368.
Setchell, K. D. R., & Heubi, J. E. (2018). Cholesterol absorption inhibitors and lipid management: Clinical applications. Journal of Lipid Research, 59(6), 1013-1025.
Stojanovic, M., & Stojanovic, A. (2020). The impact of beta-blockers on exercise performance in athletes. Sports Medicine, 50(8), 1433-1446.
Wu, J., & Duan, Y. (2020). PPARδ agonists and their therapeutic potential in metabolic disorders. European Journal of Pharmacology, 882, 173285.
